What Invanz treats: main uses and benefits

Invanz (Ertapenem) is a systemic antibacterial agent of the carbapenem class used to manage infections caused by susceptible bacteria. Its use is primarily focused on managing conditions that generally require supportive systemic treatment. Its application is considered relevant in contexts involving heightened systemic burden.

Management of Complicated Deep-Tissue Infections

This medicine is applied across domains where additional symptomatic support is needed in cases of complicated infections, notably those involving the abdomen, pelvis, and extensive skin and soft tissue (including diabetic foot infections without bone involvement). It helps address symptom clusters that may become intense or disruptive, such as high fever, severe localized pain, and symptoms related to systemic imbalance. The medication may assist with the management of the underlying complex bacterial cause, which generally contributes to easing the overall symptom load.

Targeting Acute Respiratory and Urogenital Challenges

Invanz is commonly used to help with acute or disruptive episodes, including community-acquired pneumonia and complicated urinary tract infections like pyelonephritis. Its use is considered relevant for managing acute or disruptive episodes across appropriate patient groups. In adults, it is also used for the prophylaxis of surgical site infection following elective colorectal surgery, which generally contributes to improved day-to-day comfort during symptomatic periods.

---

Quick Fact: Symptom Management: Systemic Imbalance

Invanz is considered relevant in settings marked by temporary physiological imbalance, applied when symptoms create noticeable physiological strain and interfere with daily functioning, such as in cases of complicated pyelonephritis (kidney infection).

Who can and cannot use Invanz? (Ertapenem)

The official regulatory labeling defines strict population eligibility based on allergies, age, and organ function status.

Classification	Eligibility Status Determined by Regulatory Authorities
Absolute Contraindication	Patients with known hypersensitivity to Ertapenem, to any other carbapenem antibiotic, or a history of severe allergic reaction (e.g., anaphylaxis) to any other beta-lactam antibiotic (like penicillins or cephalosporins). Use for intramuscular (IM) administration is also contraindicated in patients with a known allergy to amide-type local anesthetics (e.g., lidocaine).
Established Use	Adults (18 years and older), Adolescents (13 to 17 years), and Children aged 3 months to 12 years are the approved age groups. Use is generally permitted in older adults, provided they do not have severe renal impairment.
Restricted/Conditional Use	Adults with severe renal impairment (Creatinine Clearance le 30 mL/min/1.73 m^2) are subject to restriction; the EMA states use is not recommended due to insufficient data, while the FDA requires a mandatory dose reduction. Caution is also advised for patients with CNS disorders, such as a history of seizures.
Use Not Established	Infants younger than 3 months of age are not recommended for use, as safety and efficacy have not been established in this population.
Pregnancy/Lactation	Invanz should not be used in pregnancy unless the potential benefit justifies the risk; breastfeeding is not recommended while receiving treatment, as the medicine is excreted in human milk.

Interactions with other medicines and products

Interaction patterns for Invanz (Ertapenem) are primarily defined by documented effects on drug clearance and physical incompatibility constraints as stated in official labeling.

Documented Pharmacokinetic Interactions

The medicine Probenecid is known to interact with Ertapenem through competition for active renal tubular secretion. Co-administration results in a pharmacokinetic interaction that reduces the renal clearance of Ertapenem, leading to an increase in its plasma concentration and a prolongation of its elimination half-life. Official regulatory information states that co-administration with Probenecid is not recommended.

Other Significant Drug Interactions

Interacting Substance	Regulatory Classification & Outcome
Valproic Acid / Divalproex Sodium	Ertapenem significantly reduces the serum concentration of Valproic Acid, an interaction classified as a serious warning due to the potential loss of seizure control.
Diluents Containing Dextrose	Physical incompatibility exists; the product must not be mixed or co-infused with other medications or with intravenous diluents containing dextrose.

| CYP450 Enzymes | Regulatory data indicates Ertapenem does not inhibit metabolism mediated by the major cytochrome P450 isoforms. |

No interactions are explicitly documented in official labeling regarding food, alcohol, or common herbal products.

The action of Ertapenem is defined by a rapid, targeted strategy focused entirely on the bacterial cell's integrity, resulting in the bactericidal consequence against susceptible pathogens.

Covalent Blockade of Cell Wall Assembly

Ertapenem operates by forming a stable, covalent bond with Penicillin-Binding Proteins (PBPs), specifically inhibiting key bacterial transpeptidase enzymes like PBP 2 and PBP 3. This engagement directly blocks the final, crucial transpeptidation step in the peptidoglycan synthesis pathway, instantly halting the construction of the bacterial cell wall. This molecular intervention sets the stage for the cell's physical collapse.

Initiating the Bactericidal Cascade

The failure of the cell wall structure leads to a decisive mechanistic cascade. The inhibition of the PBPs triggers the bacterium's own autolytic enzymes while simultaneously exposing the weakened cell to overwhelming osmotic pressure. This combined action results in rapid cell lysis (rupture), achieving a bactericidal effect that removes the susceptible microbial cell from the biological system.

️ Mechanistic Limitations

The mechanism is biologically constrained by bacterial defense systems. Resistance emerges either when enzymes like carbapenemases chemically inactivate Ertapenem, or when changes in the bacterial outer membrane porins physically exclude the drug, preventing it from reaching the PBP targets and initiating the cell-lysing cascade.

How to use Invanz

Invanz (Ertapenem) is a parenteral medication, meaning it must be administered by injection or infusion in a clinical setting; it is not available as an oral tablet. Official instructions for use are highly specific regarding the route, dose, and preparation, ensuring standardized administration.

Administration and Dosing

Category	Instruction
Route of Administration	Intravenous (IV) Infusion or Intramuscular (IM) Injection.
Standard Adult Dose	1 gram (g) once daily.
Pediatric Dose	15 mg/kg given twice daily (maximum 1 g/day), for ages 3 months to 12 years.

---

Procedural and Time Requirements

• IV Infusion Rate: The dose must be infused intravenously over a period of 30 minutes.
• Preparation: The medicine is supplied as a lyophilized powder that requires immediate reconstitution and dilution prior to administration. For IV use, diluents containing alpha-D-glucose (dextrose) are prohibited.
• IM Preparation: Intramuscular use requires reconstitution with 1% lidocaine hydrochloride solution (without epinephrine) and should be administered within 1 hour of preparation.
• Course Duration: Therapy typically ranges from 3 to 14 days, although specific infection types, such as diabetic foot infections, may require up to 4 weeks of therapy. For adults undergoing elective colorectal surgery, a single 1 g dose is administered one hour prior to the surgical incision as prophylaxis.

---

Dose Adjustment

Official guidelines mandate a dosage reduction for adult patients with advanced renal insufficiency (creatinine clearance le 30 mL/min/1.73 m^2) to 500 mg once daily. A supplementary 150 mg dose is recommended following haemodialysis if the primary dose was given within six hours before the session.

Research Evidence / Overview of Studies for Invanz

Research Evidence for Major Complicated Infections

The research for Invanz was evaluated in the context of serious infections, primarily using Randomized Controlled Trials (RCTs). These studies were designed to explore how symptoms change over time and compare the medicine to other study agents. The main outcomes studies monitored involved measuring clinical cure and measuring microbiological success (the eradication of the bacteria causing the infection).

Studies on Complicated Abdominal and Pelvic Infections

Invanz was evaluated in trials involving adults diagnosed with complicated intra-abdominal infections, which are conditions associated with acute or disruptive episodes. The research also examined outcomes in women with acute pelvic infections. The evidence reflects the patterns observed in patients with mild-to-moderate severity cases, but research remains limited when it comes to the most severe or complex abdominal infections.

Studies on Complicated Skin, Soft Tissue, and Diabetic Foot Infections

For complicated skin and soft tissue infections (cSSTI), including specific types of diabetic foot infections that do not involve the bone, these trials research examined outcomes related to physical discomfort and the clinical response in adults. Results apply only to the populations studied and do not include individuals where the infection has spread to the bone (osteomyelitis), as those cases were routinely excluded from the main trials.

Studies on Respiratory and Urinary Tract Infections

The use of Invanz was studied in trials involving acute and disruptive episodes, such as community-acquired pneumonia (CAP) and complicated urinary tract infections (cUTI). For cUTI, the evidence was observed in some studies to have variability in microbiological eradication rates. Further study is ongoing regarding some of the detailed eradication metrics.

---

Evidence for Surgical Site Infection Prevention

Research for this use consists of Randomized Controlled Trials that studies monitored the rate of infection at the surgical site following a single dose given just before elective colorectal surgery. Findings describe patterns observed in the studies regarding the frequency of infection occurrence. Results apply only to the populations studied in this particular surgical setting.

---

Long-Term Follow-up and Durability of Response

The primary research trials focused on measuring infection clearance and symptom resolution over relatively short, defined time intervals. Therefore, there is limited information for long-term outcomes regarding the durability of the response. The research generally provided context on short-term changes, but long-term outcomes are not fully established regarding infection recurrence months or years later. The primary research goal appeared to be short-term clinical assessment.

---

Evidence in Special Populations

Invanz was evaluated in certain special populations, including pediatric patients (3 months and older) for intra-abdominal infections, CAP, and cUTI. Research has examined the use of Invanz in older adults. However, data for certain groups remain insufficient, specifically for patients with the most severe or complicated disease presentation who were often excluded from the original RCTs.

---

Research Gaps and Areas of Uncertainty

For Invanz, evidence quality varies across studies depending on the specific infection being examined. Comparative evidence is lacking in some areas, and findings were mixed regarding specific microbiological outcomes. Overall, there is limited information for long-term outcomes and sample sizes were modest for certain high-risk subgroups. Studies help show what has been observed so far, but findings describe group patterns, not personal outcomes, and research does not determine whether an individual will respond similarly to the patterns observed in the trials.

Common questions about Invanz (FAQ)

Q: Is Invanz the same kind of antibiotic as penicillin?

A: Invanz (Ertapenem) is classified in the same broad family of medicines, the beta-lactam antibiotics, which also includes penicillins. However, official sources categorize Invanz as a carbapenem antibiotic, a distinct and usually more specialized subgroup within that family. This distinction is based on the medicine's molecular structure and its targeted activity.

---

Q: What should I know about taking other medicines with Invanz?

A: Regulatory documents highlight two key medicines regarding interactions. Co-administration with probenecid (a gout medicine) is generally not recommended because it can compete with Invanz for clearance from the body. Additionally, the use of Invanz has been described as leading to a significant reduction in the concentration of valproic acid or divalproex sodium, an interaction that may affect seizure control.

---

Q: Does Invanz affect kidney function or liver function?

A: Official reports indicate that common laboratory changes observed include an increase in certain liver enzymes (ALT and AST). Rare reports have also noted effects related to kidney function, such as renal insufficiency. The potential for these effects is noted in official documentation, and the healthcare team typically monitors these laboratory values.

---

Q: Is Invanz known to cause C. difficile infection?

A: Yes, official warnings note that Invanz carries a risk of Clostridioides difficile-associated diarrhoea (CDAD). This is a potential effect noted in official warnings for Invanz, as it can disrupt the natural balance of bacteria in the digestive system. CDAD can range from mild diarrhea to a more serious intestinal condition.

---

Q: How long after the last dose does Invanz stay in the system?

A: Pharmacokinetic studies indicate how quickly the active medicine is cleared from the body. The time it takes for the concentration to reduce by half (the elimination half-life) is approximately 3.5 to 4 hours. This elimination process is primarily managed through the kidneys.

---

Q: Is it common to feel tired or weak while receiving Invanz?

A: Official documents list feeling tired or weak (sometimes referred to as asthenia or fatigue) as an Uncommon side effect. This means the effect may be observed in up to 1 in 100 people who receive the medication, according to regulatory data.

---

Q: What research is available on Invanz for preventing infections after surgery?

A: Official research evidence establishes that Invanz has been studied and approved for use in preventing infections following certain procedures. Specifically, a single dose is used for prophylaxis (prevention) of infection in adult patients undergoing elective colorectal surgery.

---

Q: How does Invanz compare to other 'strong' antibiotics I hear about?

A: Invanz (Ertapenem) belongs to the carbapenem class of antibiotics, which is typically used for specific, complicated bacterial infections. This classification reflects the drug's potent, broad-spectrum activity and the importance of using it selectively to manage bacterial threats.

---

Q: What foods or supplements should be avoided while using Invanz?

A: According to the official prescribing information, there are no specific documented interactions that require the avoidance of particular foods, alcohol, or common herbal products while using Invanz.

---

Q: Does Invanz affect blood sugar levels?

A: Official documents note that a drop in blood sugar, known as hypoglycaemia, has been reported as a rare potential side effect of Invanz. This potential for a change in blood sugar is noted in the official prescribing information.

---

Q: Can Invanz cause confusion or changes in mood?

A: Official adverse reaction reports list potential effects on the central nervous system. Confusion and insomnia (difficulty sleeping) are listed as common side effects. Less commonly, effects like agitation or anxiety have also been reported.

---

Q: What should a patient do if they notice swelling or irritation at the injection site?

A: Official patient information notes that local reactions, such as pain, redness, or irritation at the injection site, are very common adverse reactions. Official patient information describes that these effects should be reported to the healthcare team.

---

Q: Does Invanz treat infections caused by MRSA?

A: Official prescribing criteria state that Invanz is not active against certain bacteria. Specifically, it is not used to treat infections caused by Methicillin-resistant Staphylococcus aureus (MRSA), as it does not target this type of organism.

---

Q: Are there any restrictions on driving or operating machinery while on Invanz?

A: Official patient information contains a warning that because side effects like dizziness and sleepiness have been reported, caution is necessary regarding activities requiring full attention, such as driving or using tools.

How to Store and Dispose of Invanz

The way Invanz (ertapenem) is stored and handled is crucial for maintaining its stability and effectiveness. The unopened powder for injection must be stored in a refrigerator, strictly maintained between 2 °C and 8 °C. It is essential not to freeze the product at any stage.

Once reconstituted and diluted for intravenous infusion using 0.9% Sodium Chloride, the solution’s stability is limited. The prepared solution must be used within six hours if kept at room temperature (up to 25 °C) or within 24 hours if refrigerated. If the solution is refrigerated, it must then be administered within four hours after being removed.

Any solution that has been prepared but not administered within these timeframes must be discarded. To ensure safety, all unused Invanz product and waste materials must be disposed of according to local regulations and requirements.